Is Tecnis Eyhance a real innovation or just another overhyped IOL?
- Oleksii Sologub
- May 18
- 2 min read
In the growing category of so-called “enhanced monofocal” IOLs — including Tecnis Eyhance, RayOne EMV, B+L Aspire and similar — many patients and even surgeons are wondering whether these lenses truly offer something better than standard monofocals, or if it’s all just smart branding.
In this video, I take a deep look at what makes Eyhance different from regular monofocal IOLs, and why in some cases it may seem to “not work” — especially when judged with the wrong tools or expectations.
Here’s the core idea:
✅ Eyhance does improve intermediate vision, but this improvement is subtle and can be easily missed if residual refraction is not precisely measured and corrected. Autorefractors — especially after cataract surgery — often misread small hyperopic shifts in patients with enhanced monofocals, leading to the false impression that the patient is plano when they are actually +0.50D. This can fully mask the added intermediate performance.
✅ Unlike basic monofocals, Eyhance has a flatter defocus curve, which gives surgeons more flexibility in hitting their refractive targets without a steep drop in visual acuity. This design allows for some refractive tolerance while still maintaining decent intermediate vision.
❗ However, if the refractive target is slightly off, or if it is incorrectly assessed as “plano” based on autorefractor readings, both the surgeon and patient may conclude Eyhance doesn’t offer anything better than a standard IOL — which isn’t true when properly assessed.
In this video, I walk through real examples, practical advice, and common misconceptions around Eyhance and other enhanced monofocals. I also explain how to interpret patient feedback, measure residual refraction correctly, and make sense of what’s happening when expectations and outcomes don’t align.
I will also cover the worst-case scenario of significant refractive target shift to hyperopia, as you may see in that example below:

It’s a nuanced explanation based on over 6 years of experience with Eyhance across multiple markets and patient types.
If you’re a patient researching your IOL options — or a surgeon who wants to understand why some patients report no benefit from enhanced monofocals — this video is for you.
▶️ Watch the full video at IOL-adviser YouTube channel:
Learn more and explore case studies on my website: iol-adviser.com Oleksii at IOL-adviser Follow me at Reddit
Comentarios